Phio Pharmaceuticals granted U.S. patent allowance for PH-894
Patent allowance for PH-894, a preclinical candidate in oncology, follows prior regulatory approvals for Phio’s RNAi platform.
Phio Pharmaceuticals Inc. said on Monday it received a notice of patent allowance from the U.S. Patent and Trademark Office for PH-894, a preclinical oncology candidate.
The patent allowance covers methods of use for PH-894, which is part of Phio’s self-delivering RNAi (INTASYL) platform. The company has previously received regulatory approvals in the U.S. and Europe for its RNAi platform, which is designed to silence disease-causing genes without requiring delivery vehicles such as lipids or nanoparticles.
Phio Pharmaceuticals, based in Marlborough, Massachusetts, develops RNA-based therapies for cancer and other diseases. PH-894 targets specific genetic pathways implicated in tumor growth, according to prior disclosures. The company has not disclosed a timeline for potential clinical trials or commercialization of PH-894.
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →